SG Americas Securities
ALLO icon

SG Americas Securities’s Allogene Therapeutics ALLO Stock Holding History

SG Americas Securities’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$145K Buy
69,920
+54,530
+354% +$120K ﹤0.01% 2925
2026
Q1 		$38K Sell
15,390
-8,577
-36% -$17.2K ﹤0.01% 3049
2025
Q4 		$33K Buy
23,967
+5,456
+29% +$7.2K ﹤0.01% 3410
2025
Q3 		$23K Sell
18,511
-76,206
-80% -$90.9K ﹤0.01% 3276
2025
Q2 		$107K Buy
94,717
+56,255
+146% +$74.8K ﹤0.01% 2610
2025
Q1 		$56K Sell
38,462
-11,472
-23% -$21.6K ﹤0.01% 3209
2024
Q4 		$106K Buy
49,934
+2,967
+6% +$7.32K ﹤0.01% 2700
2024
Q3 		$132K Buy
46,967
+33,651
+253% +$89.7K ﹤0.01% 2832
2024
Q2 		$31K Sell
13,316
-21,842
-62% -$64.4K ﹤0.01% 2738
2024
Q1 		$157K Sell
35,158
-18,326
-34% -$76.5K ﹤0.01% 2160
2023
Q4 		$172K Buy
+53,484
New +$152K ﹤0.01% 2300
2023
Q2 		– Sell
-16,172
Closed -$80K – 2251
2023
Q1 		$80K Buy
16,172
+4,400
+37% +$28.2K ﹤0.01% 2978
2022
Q4 		$74K Buy
11,772
+328
+3% +$3.04K ﹤0.01% 2785
2022
Q3 		$124K Sell
11,444
-61,063
-84% -$830K ﹤0.01% 2687
2022
Q2 		$827K Sell
72,507
-107,111
-60% -$951K 0.01% 1467
2022
Q1 		$1.64M Buy
179,618
+55,994
+45% +$583K 0.01% 1057
2021
Q4 		$1.84M Buy
123,624
+24,770
+25% +$437K 0.01% 1142
2021
Q3 		$2.54M Buy
98,854
+20,440
+26% +$485K 0.01% 1058
2021
Q2 		$2.04M Sell
78,414
-3,592
-4% -$102K 0.01% 1108
2021
Q1 		$2.9M Sell
82,006
-21,702
-21% -$732K 0.02% 805
2020
Q4 		$2.62M Buy
103,708
+80,444
+346% +$2.62M 0.01% 909
2020
Q3 		$877K Sell
23,264
-7,168
-24% -$270K 0.01% 1262
2020
Q2 		$1.3M Sell
30,432
-21,676
-42% -$784K 0.01% 1156
2020
Q1 		$1.01M Buy
52,108
+29,411
+130% +$701K 0.01% 1283
2019
Q4 		$590K Sell
22,697
-15,673
-41% -$432K 0.01% 1634
2019
Q3 		$1.05M Buy
+38,370
New +$1.09M 0.01% 1379

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

SG Americas Securities's ALLO Position: Q2 2026 in Review

SG Americas Securities increased its Allogene Therapeutics (ALLO) stake by 354% in Q2 2026, buying an estimated $120K and bringing the position to 69,920 shares worth $145K. The position accounts for ﹤0.01% of the portfolio, ranked #2925.

SG Americas Securities first reported a position in ALLO in Q3 2019 and has held it in 26 quarters since. The position peaked at $2.9M in Q1 2021. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • SG Americas Securities held 69,920 shares of Allogene Therapeutics worth $145K as of Q2 2026.
  • SG Americas Securities bought 54,530 Allogene Therapeutics shares in Q2 2026, an estimated $120K.
  • Allogene Therapeutics made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #2925 holding.
  • SG Americas Securities first reported a position in Allogene Therapeutics in Q3 2019 and has held it in 26 quarters since.
  • SG Americas Securities's Allogene Therapeutics position peaked at $2.9M in Q1 2021.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.